Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96
| Autor: | Tom Van De Casteele, Don Kilby, Adriano Lazzarin, Ralph DeMasi, Pere Domingo, Jan Fourie, Sabrina Spinosa-Guzman, Ludo Lavreys, Juan Ballesteros, Amalia Rodriguez-French, Jason Flamm, Nestor Sosa |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Aging Anti-HIV Agents HIV Infections Pharmacology Gastroenterology Drug Administration Schedule law.invention Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Darunavir Sex Characteristics Sulfonamides Ritonavir business.industry Incidence (epidemiology) Racial Groups Lopinavir Hepatitis C Hepatitis B Middle Aged medicine.disease Infectious Diseases Coinfection HIV-1 RNA Viral Drug Therapy Combination Female business medicine.drug |
| Zdroj: | HIV clinical trials. 12(6) |
| ISSN: | 1528-4336 |
| Popis: | ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r patients.Patients received once-daily DRV/r plus fixed-dose tenofovir/emtricitabine. Week 96 efficacy and safety data were analyzed by gender (males, n=239; females, n=104), age (≤30, n=115; 31-45, n=175;45, n=53), race (Asian, n=44; Black, n=80; Caucasian/White, n=137; Hispanic, n=77), and hepatitis B and/or C virus coinfection (n=43).Week 96 virologic response rates (HIV-1 RNA50 copies/mL) were as follows: gender: 79% for both males and females; age: 72% (≤30), 81% (31-45), and 89% (45); race: 96% (Asian), 71% (Black), 77% (Caucasian/White), and 79% (Hispanic); coinfection status: 72% (coinfected) and 80% (non-coinfected). The incidence of treatment-related adverse drug reactions (ADRs) and laboratory abnormalities were comparable across gender, age, and race subgroups. Coinfected patients had a higher incidence of liver-related ADRs than non-coinfected patients.DRV/r 800/100 mg qd is an effective, well-tolerated treatment option for treatment-naïve patients of different gender, age, race, or coinfection status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|